mosedipimod

Mosedipimod is a synthetic monoacetyldiacylglyceride, originally derived from Sika deer antler, and developed as an oral small molecule immunomodulator. It accelerates endocytic trafficking of pattern recognition receptors, facilitating the removal of pathogen-associated and damage-associated molecular patterns (PAMPs/DAMPs), which leads to reduced inflammation and fibrosis in preclinical models. Mosedipimod stimulates calcium influx into T lymphocytes, increases cytokine production (including IL-2, IL-4, IL-12, IFN-gamma, GM-CSF), and promotes proliferation of hematopoietic stem cells as well as immune cells such as T/B lymphocytes and dendritic cells. It also enhances natural killer cell activity and inhibits toll-like receptor 4 expression on tumor cells. The drug is being investigated for supportive care in chemotherapy-induced neutropenia, chemoradiation-induced oral mucositis, COVID-19 pneumonia/acute respiratory distress syndrome (ARDS), acute radiation syndrome, atopic dermatitis (with a planned Phase II trial), among other indications[1][2][3][4][5][6][7].

Brand names

EC-18EC18EC 18

Other names

1-palmitoyl-2-linoleoyl-3-acetyl-rac-glycerolmosedipimod